Tremor
TrialsCompanies

Not investment advice.

Tremor shows what changed in public records. It never tells anyone to buy or sell. Many trial edits are harmless paperwork. Data from ClinicalTrials.gov, the SEC, and the Federal Register.

PrivacyTerms

COGTCogent Biosciences, Inc.Running, no new patients

(Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis

SSM · Mastocytosis, Indolent · Mastocytosis, Systemic · Mastocytosis · ISM · BMM · Smoldering Systemic Mastocytosis · Bone Marrow Mastocytosis

10Calmworry score, out of 100

No strong warning signs right now. The score counts warning signs; it is not a prediction.

Why this score

  • Main results were due May 2025, none posted yet

    Counts until it's fixed

    +10
Worry score10

Score over time

Stage
Phase 2
Patients
237 (planned)
Started
Jun 27, 2022
Main results expected
May 22, 2025
Fully finished
Jan 2030
Results posted
not yet

What counts as success

The trial's main goal(s), called the “primary outcome.”

  • Part 1: Determine recommended dose of bezuclastinib (CGT9486) in subjects with NonAdvSM

    Measured over: 3 months

  • Part 2: Efficacy of bezuclastinib at the selected dose versus placebo

    Measured over: 24 Weeks

  • Part 3: Safety and tolerability of bezuclastinib as assessed by number of adverse events

    Measured over: Up to 5 years

Changes Tremor has spotted

No changes since Tremor started watching this trial.
Show details (technical version)

Score inputs

  • results_overdue: base 10, now 10, since 2025-05-22, no fading

Raw record changes

  • none yet

Trial ID NCT05186753 · record last updated 2026-10-22 · checked 2026-11-09 15:47 UTC

See the official record on ClinicalTrials.gov (NCT05186753) ↗